Biogen Inc (BIIB) |
|
270.28 -3.56 (-1.3%)
|
01-21 01:08 |
|
Open: |
274.31 |
Pre. Close: |
273.84 |
|
High:
|
274.54 |
Low:
|
267.665 |
|
Volume:
|
1,293,364 |
Market Cap:
|
41,591M |
|
|
|
|
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
274.842 - 277.081 |
277.081 - 278.584 |
|
Low:
|
263.031 - 265.498 |
265.498 - 267.153 |
|
Close:
|
267.045 - 270.872 |
270.872 - 273.442 |
|
Technical analysis |
as of: 2021-01-20 4:44:56 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 330.08 One year: 385.53 |
| Support: |
Support1: 255.28 Support2: 238.40 |
| Resistance: |
Resistance1: 282.60 Resistance2: 330.08 |
| Pivot: |
258.25  |
| Moving Average: |
MA(5): 273.38 MA(20): 255.71
MA(100): 263.54 MA(250): 283.84 |
| MACD: |
MACD(12,26): 6.61 Signal(9): 3.88 |
| Stochastic oscillator: |
%K(14,3): 79.00 %D(3): 84.65 |
| RSI: |
RSI(14): 62.45 |
| 52-week: |
High: 374.99 Low: 223.25 Change(%): -4.9 |
| Average Vol(K): |
3-Month: 177001 10-Days: 141797 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.BIIB has closed below upper band by 27.2%. Bollinger Bands are 24.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 14 Jan 2021
Biogen Stock Jumps Amid Signs Alzheimer’s Drug Discussions With FDA Continue - Barron's
Thu, 14 Jan 2021
Do Institutions Own Biogen Inc. (NASDAQ:BIIB) Shares? - Simply Wall St
Wed, 13 Jan 2021
Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Mon, 11 Jan 2021
Biogen Inc. (BIIB) Rises 5.93% for January 11 - Equities.com
Mon, 11 Jan 2021
Biogen Inc. (BIIB) Management Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha
Mon, 11 Jan 2021
Biogen's stock is up 5% after Lilly reports positive data from an Alzheimer's study - MarketWatch
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers General |
| Shares Out. (M) |
154 |
| Shares Float (M) |
153 |
|
% Held by Insiders
|
0.63 |
|
% Held by Institutions
|
87.89 |
|
Shares Short (K)
|
3,850 |
|
Shares Short P. Month (K)
|
3,710 |
Stock Financials |
|
EPS
|
30.380 |
|
EPS Est This Year
|
22.100 |
|
EPS Est Next Year
|
23.820 |
|
Book Value (p.s.)
|
69.910 |
|
Profit Margin
|
35.63 |
|
Operating Margin
|
46.90 |
|
Return on Assets (ttm)
|
15.9 |
|
Return on Equity (ttm)
|
41.6 |
|
Qtrly Rev. Growth
|
-6.2 |
|
Gross Profit (p.s.)
|
80.712 |
|
Sales Per Share
|
92.670 |
|
EBITDA (p.s.)
|
46.465 |
|
Qtrly Earnings Growth
|
-54.60 |
|
Operating Cash Flow (M)
|
6,560 |
|
Levered Free Cash Flow (M)
|
4,680 |
Stock Valuations |
|
PE Ratio
|
8.90 |
|
PEG Ratio
|
6.24 |
|
Price to Book value
|
3.87 |
|
Price to Sales
|
2.92 |
|
Price to Cash Flow
|
6.34 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
